AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25272582 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of osteoporosis and its risk factors among subjects with osteoporosis
Number of subjects: 150
Study 25272582 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy product consumption
Number of subjects: 150
Study 25272582 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 150
Study 25272582 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractures reported in the last year
Number of subjects: 150
Study 22517399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide 500 mg with standard radiation and temozolomide
Number of subjects: 112
Study 22517399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide 2000 mg with standard radiation and temozolomide
Number of subjects: 112
Study 22517399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide (both doses) with standard radiation and temozolomide
Number of subjects: 112
Study 22517399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide with standard radiation and temozolomide for patients with methylated MGMT status
Number of subjects: 112
Study 22517399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide with standard radiation and temozolomide for patients with unmethylated MGMT status
Number of subjects: 112
Study 22517399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide with standard radiation and temozolomide for patients aged ≤70 years
Number of subjects: 112
Study 22517399 — intervention group
Group type: COMPARATOR
Intervention: EORTC trial (historical control)
Number of subjects: 112
Study 19751434 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacilli supplementation
Number of subjects: 1372
Study 19751434 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy without Lactobacilli
Number of subjects: 1372
Study 17931323 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led interventions
Number of subjects: 22
Study 17931323 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led care
Number of subjects: 22
Study 15040646 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrolide therapy
Number of subjects: 12032
Study 12409967 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol infusion (0.625, 1.25 and 2.5 microg/kg per min for 10 min each)
Number of subjects: 27
Study 12409967 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol infusion
Number of subjects: 27
Study 12409967 — intervention group
Group type: COMPARATOR
Intervention: Glycyrrhetinic acid (GRA; 500 mg orally 2.5 h before the study)
Number of subjects: 27
Study 12409967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 9809729 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide GITS (5 to 20 mg)
Number of subjects: 569
Study 11256901 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) added peritoneal dialysis (PD)
Number of subjects: 40
Study 11256901 — intervention group
Group type: COMPARATOR
Intervention: Standard peritoneal dialysis (PD)
Number of subjects: 40
Study 2758758 — intervention group
Group type: EXPERIMENTAL
Intervention: 57 mm thermal clearance probe
Number of subjects: 41
Study 2758758 — intervention group
Group type: COMPARATOR
Intervention: 18 mm thermal clearance probe
Number of subjects: 41
Study 1000519 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-dichlorodiammineplatinum(II) high-dose schedule (30 mg/m2 daily for 3 days every 4 weeks)
Number of subjects: 34
Study 1000519 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-dichlorodiammineplatinum(II) low-dose schedule (30 mg/m2 once every 2-3 weeks)
Number of subjects: 34
Study 29654913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 599
Study 27401882 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged release oxycodone/naloxone (OXN PR)
Number of subjects: 276
Study 27401882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 24836758 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment groups (specific treatments not detailed)
Number of subjects: 59
Study 24836758 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 59
Study 24836758 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment, acceptability, and attrition rates
Number of subjects: 59
Study 24836758 — intervention group
Group type: EXPERIMENTAL
Intervention: Roland Morris Disability Questionnaire
Number of subjects: 59
Study 22402971 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted fluid regimen (R group)
Number of subjects: 179
Study 22402971 — intervention group
Group type: COMPARATOR
Intervention: Standard fluid regimen (S group)
Number of subjects: 179
Study 20553586 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigileo group (SVV guided fluid optimization)
Number of subjects: 120
Study 20553586 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigileo group
Number of subjects: 120
Study 20553586 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 18666721 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% aqueous gentian violet (GV)
Number of subjects: 30
Study 18666721 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel dressing
Number of subjects: 30
Study 16439809 — intervention group
Group type: COMPARATOR
Intervention: White petrolatum (glycerin) as positive control
Number of subjects: 18
Study 16439809 — intervention group
Group type: EXPERIMENTAL
Intervention: Products containing dimethicone
Number of subjects: 18
Study 16439809 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide‐based products
Number of subjects: 18
Study 16439809 — intervention group
Group type: EXPERIMENTAL
Intervention: Water‐in‐oil petrolatum‐based product
Number of subjects: 18
Study 12856481 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased digoxin synthesis with upregulated tryptophan catabolism (increased serotonin, strychnine, nicotine) and downregulated tyrosine catabolism (decreased dopamine, noradrenaline, morphine) in chronic insomnia with right hemispheric dominance
Number of subjects: 0
Study 12856481 — intervention group
Group type: COMPARATOR
Intervention: Reduced digoxin synthesis with downregulated tryptophan catabolism (decreased serotonin, strychnine, nicotine) and upregulated tyrosine catabolism (increased dopamine, noradrenaline, morphine) in normal sleep patterns with left hemispheric dominance
Number of subjects: 0
Study 11019348 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital group (discharged earlier)
Number of subjects: 78
Study 8973666 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral alprostadil (125, 250, 500, and 1000 micrograms)
Number of subjects: 68
Study 8973666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 1574768 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast preservation
Number of subjects: 1112
Study 1574768 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 1112
Study 1574768 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-involved margins
Number of subjects: 1112
Study 1574768 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmembrane proteins (EGFR, p-185, p-148, c-myc)
Number of subjects: 1112
Study 2865009 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox olamine cream 1%
Number of subjects: 145
Study 2865009 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 145
Study 2865009 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole cream 1%
Number of subjects: 145
Study 30078618 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg)
Number of subjects: 539
Study 30078618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 539
Study 26943843 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion threshold of 10 g/dl
Number of subjects: 200
Study 26943843 — intervention group
Group type: COMPARATOR
Intervention: Transfusion threshold of 7 g/dl
Number of subjects: 200
Study 24942833 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher NT-proBNP (≥450ng/l)
Number of subjects: 5205
Study 22401633 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoxel (Dzherelo) administered once-daily along with TB drugs
Number of subjects: 0
Study 22401633 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 22401633 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoxel (Dzherelo)
Number of subjects: 0
Study 20590480 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacopa monnieri (BacoMind(TM)) 300 mg/day
Number of subjects: 98
Study 20590480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 18334874 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time PCR for H. pylori detection
Number of subjects: 103
Study 18334874 — intervention group
Group type: COMPARATOR
Intervention: Urea breath test (UBT)
Number of subjects: 103
Study 18334874 — intervention group
Group type: COMPARATOR
Intervention: Serological testing
Number of subjects: 103
Study 18334874 — intervention group
Group type: COMPARATOR
Intervention: Histology
Number of subjects: 103
Study 18334874 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time PCR ureaseA/beta-globin ratio
Number of subjects: 103
Study 18334874 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time PCR for bacterial density
Number of subjects: 103
Study 18334874 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time PCR VacA s1
Number of subjects: 103
Study 18334874 — intervention group
Group type: EXPERIMENTAL
Intervention: CagA results
Number of subjects: 103
Study 18334874 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic profiles (VAC/GAC)
Number of subjects: 103
Study 15819764 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg intrathecal morphine
Number of subjects: 70
Study 15819764 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg intrathecal morphine
Number of subjects: 70
Study 12439518 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate bacterial vaginosis
Number of subjects: 749
Study 12439518 — intervention group
Group type: EXPERIMENTAL
Intervention: Frank bacterial vaginosis
Number of subjects: 749
Study 12439518 — intervention group
Group type: EXPERIMENTAL
Intervention: Any detectable defensin
Number of subjects: 749
Study 12439518 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of leukocytes in vaginal fluids
Number of subjects: 749
Study 10506854 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 30
Study 10506854 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 30
Study 10506854 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 30
Study 8947397 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet use (Group I)
Number of subjects: 40
Study 8947397 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet (Group II)
Number of subjects: 40
Study 8947397 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group I and Group II)
Number of subjects: 40
Study 1911676 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 ml of 2% lignocaine containing 1:80000 adrenaline
Number of subjects: 20
Study 1911676 — intervention group
Group type: COMPARATOR
Intervention: 4.0 ml of 2% lignocaine (adrenaline-free)
Number of subjects: 20
Study 7076989 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) 2 gm/day for 3 days
Number of subjects: 8
Study 7076989 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid (AA) 0, 1, 2, and 4 gm/day
Number of subjects: 8
Study 7076989 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 8
Study 31567881 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis plus rivaroxaban (CDT)
Number of subjects: 0
Study 31567881 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban alone (control)
Number of subjects: 0
Study 28639834 — intervention group
Group type: EXPERIMENTAL
Intervention: health‐IAT (health‐implicit association test)
Number of subjects: 1004
Study 28639834 — intervention group
Group type: EXPERIMENTAL
Intervention: health‐IAT
Number of subjects: 1004
Study 25703452 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 270
Study 25703452 — intervention group
Group type: COMPARATOR
Intervention: Pre-ART
Number of subjects: 270
Study 24380765 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Undulating Periodized (DUP) training
Number of subjects: 32
Study 24380765 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonperiodized (NP) training
Number of subjects: 32
Study 24380765 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear Periodized (LP) training
Number of subjects: 32
Study 24380765 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 32
Study 24380765 — intervention group
Group type: EXPERIMENTAL
Intervention: All training groups (NP, LP, DUP)
Number of subjects: 32
Study 22324488 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg, once daily for 3 days)
Number of subjects: 28
Study 22324488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 22324488 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 28
Study 19507408 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief educational video about prostate cancer screening
Number of subjects: 0
Study 17202559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylphenidate (0.5 mg/kg)
Number of subjects: 78
Study 17202559 — intervention group
Group type: COMPARATOR
Intervention: Comparison subjects (no intervention)
Number of subjects: 78
Study 17202559 — intervention group
Group type: COMPARATOR
Intervention: Cocaine abusers (no intervention)
Number of subjects: 78
Study 15893916 — intervention group
Group type: EXPERIMENTAL
Intervention: Rutgers acquired equivalence task (face-fish task)
Number of subjects: 43
Study 15893916 — intervention group
Group type: EXPERIMENTAL
Intervention: California Verbal Learning Test (CVLT)
Number of subjects: 43
Study 15893916 — intervention group
Group type: EXPERIMENTAL
Intervention: n-back working memory test
Number of subjects: 43
Study 15893916 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus-response learning
Number of subjects: 43
Study 15893916 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily chlorpromazine-equivalent dose of antipsychotics
Number of subjects: 43
Study 11956540 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 50
Study 11956540 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 50
Study 9583339 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet treatment (DT)
Number of subjects: 219
Study 9583339 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondiet treatment (NDT)
Number of subjects: 219
Study 9583339 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 219
Study 9583339 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet treatment (DT) and Nondiet treatment (NDT)
Number of subjects: 219
Study 7643302 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy mood
Number of subjects: 0
Study 7643302 — intervention group
Group type: COMPARATOR
Intervention: Neutral mood
Number of subjects: 0
Study 7643302 — intervention group
Group type: COMPARATOR
Intervention: Sad mood
Number of subjects: 0
Study 2000055 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 15
Study 2000055 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 15
Study 2000055 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 15
Study 6240831 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg celiprolol HCl + 25 mg chlorthalidone
Number of subjects: 18
Study 6240831 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg atenolol + 25 mg chlorthalidone
Number of subjects: 18
Study 30535623 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple CARE for Parents of Newborns (CCP), n=188
Number of subjects: 368
Study 30535623 — intervention group
Group type: COMPARATOR
Intervention: 24-month waitlist control, n=180
Number of subjects: 368
Study 29941498 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth
Number of subjects: 421
Study 27098143 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraperitoneal approach
Number of subjects: 60
Study 27098143 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal approach
Number of subjects: 60
Study 25278405 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour reports filled out by nurses daily
Number of subjects: 12
Study 22776872 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (Pla)
Number of subjects: 0
Study 22776872 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (Rebox)
Number of subjects: 0
Study 20802340 — intervention group
Group type: EXPERIMENTAL
Intervention: Centers for Epidemiology Studies for Depression Scale (group A)
Number of subjects: 129
Study 20802340 — intervention group
Group type: COMPARATOR
Intervention: Patient reporting of depression symptoms after a single-standardized question (group B)
Number of subjects: 129
Study 17611310 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic variceal ligation (EVL) alone
Number of subjects: 135
Study 17611310 — intervention group
Group type: COMPARATOR
Intervention: Hassab's procedure alone
Number of subjects: 135
Study 17611310 — intervention group
Group type: EXPERIMENTAL
Intervention: EVL combined with Hassab's procedure
Number of subjects: 135
Study 15881487 — intervention group
Group type: EXPERIMENTAL
Intervention: lumiracoxib 50 mg, 100 mg, 200 mg bid, 400 mg od
Number of subjects: 1356
Study 15881487 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac 75 mg bid
Number of subjects: 1356
Study 15881487 — intervention group
Group type: EXPERIMENTAL
Intervention: lumiracoxib 100 mg bid, 200 mg bid, 400 mg od
Number of subjects: 1356
Study 15881487 — intervention group
Group type: EXPERIMENTAL
Intervention: lumiracoxib 100 mg, 400 mg
Number of subjects: 1356
Study 15881487 — intervention group
Group type: EXPERIMENTAL
Intervention: lumiracoxib 400 mg
Number of subjects: 1356
Study 15881487 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1356
Study 15881487 — intervention group
Group type: EXPERIMENTAL
Intervention: ibuprofen 400 mg
Number of subjects: 1356
Study 11870017 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine, 50 mg/day
Number of subjects: 24
Study 11870017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9471487 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless steel welders
Number of subjects: 39
Study 9471487 — intervention group
Group type: COMPARATOR
Intervention: Unexposed controls
Number of subjects: 39
Study 9471487 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 39
Study 9471487 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium exposure
Number of subjects: 39
Study 9471487 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and urine nickel concentrations
Number of subjects: 39
Study 9471487 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of exposure
Number of subjects: 39
Study 8509235 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg/2 ml vials, 3 vials a day for 3 days)
Number of subjects: 60
Study 8509235 — intervention group
Group type: COMPARATOR
Intervention: Nisidin (2 ml vials, 3 vials a day for 3 days)
Number of subjects: 60
Study 2949588 — intervention group
Group type: EXPERIMENTAL
Intervention: PN 200‐110 (isradipine) 15 mg
Number of subjects: 12
Study 2949588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29769554 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation to pregnant mothers and infants
Number of subjects: 93
Study 29769554 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 93
Study 27349707 — intervention group
Group type: EXPERIMENTAL
Intervention: WM training
Number of subjects: 50
Study 27349707 — intervention group
Group type: COMPARATOR
Intervention: Control/sham training
Number of subjects: 50
Study 24505102 — intervention group
Group type: EXPERIMENTAL
Intervention: prod of 500 W
Number of subjects: 16
Study 24505102 — intervention group
Group type: EXPERIMENTAL
Intervention: prod of 600 W
Number of subjects: 16
Study 24505102 — intervention group
Group type: EXPERIMENTAL
Intervention: prod of 6.5 W/kg
Number of subjects: 16
Study 24505102 — intervention group
Group type: EXPERIMENTAL
Intervention: prod of 9.0 W/kg
Number of subjects: 16
Study 24505102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ereq of 400 W
Number of subjects: 16
Study 24505102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ereq of 340 W
Number of subjects: 16
Study 24505102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ereq of 165 W/m²
Number of subjects: 16
Study 24505102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ereq of 190 W/m²
Number of subjects: 16
Study 21951764 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 51
Study 21951764 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment (SMT)
Number of subjects: 51
Study 19954773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost treatment condition
Number of subjects: 37
Study 19954773 — intervention group
Group type: COMPARATOR
Intervention: Probability treatment condition
Number of subjects: 37
Study 18197745 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular diabetes education (program 1)
Number of subjects: 93
Study 18197745 — intervention group
Group type: COMPARATOR
Intervention: Special reminder pamphlet (program 2)
Number of subjects: 93
Study 15694232 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol 15 mg/day plus allopurinol 300 mg/day
Number of subjects: 46
Study 15694232 — intervention group
Group type: COMPARATOR
Intervention: haloperidol 15 mg/day plus placebo
Number of subjects: 46
Study 14728521 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized form with check-box entries for historical data
Number of subjects: 0
Study 14728521 — intervention group
Group type: COMPARATOR
Intervention: Free text entry
Number of subjects: 0
Study 10460070 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 80
Study 8672385 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% prilocaine
Number of subjects: 90